ASCO '23 Entrees
OncoPharm
00:00
Adjuvant OC Mertinib for Non-Small Cell Lung Cancer
The Dutch study that was funded by the Netherlands organization for health research, development, and Dutch health insurance. They say it saved the Dutch about 200,000 per person by deferring your palocyclip or your ribocyclip, etc. For those of you who don't remember, this is adjuvant OC Mertinib for EGFR mutated non-small cell lung cancer after resection plus or minus adjuvant chemo. The DFS benefit was the primary endpoint.
Transcript
Play full episode
